Human Urinary Kallirein Treat Acute Cerebral Infarction To Reseach In Clinical

Stroke reported in the lethal disease around the world ranked NO.2, which is an adult the most common cause of disability.At present except thrombolysis, fibrinolytic, anti-platelet aggregation and other treatment, cerebral infarction is lack of effective treatment, but treatment in patient with onset within six hours received thrombolytic therapy in hospital is very little ,while the complexity due to the pathogenesis of cerebral infarction and biochemical reactions of tissues and cells after the ischemic is different, so the treatment of ischemic cerebral vascular have in difficulty. Recent studies have found there is cerebral vascular reserve capacity in human .When it is met the pathological factors in the stimulation of the human, there is a potential machanism of cerebral protection by regulating blood vessel systolic and diastolic function, increasing cerebral blood flow, promoting the circulation open. So to look for the body's own material has a machanism for multi-directional, multi-target to promote the brain reserve mobilization and become the focus of scholars and hot spots.Human urinary kallikrein independently developed first class of new drugs in China ,which had independent property rights, And it has completed four phases of clinical research, its pharmacological effects include to promote angiogenesis and reduce infarction size, being anti-platelet aggregation, enhance the open collateral circulation, reduce the formation of ischemic penumbra, increase the deformability of red blood cell and to carry Oxygen capacity . People continue to explore the targeting of drug therapy in recent year. But most studies is about different locations. Due to the complexity of causes. It cannot to reach individualized treatment of patients with cerebral infarction. This study observe effect by being different subtypes and applying Human urinary kallikrein in different time. It may be guide different classification for cerebral infraction. It can guide clinical outcome and prognosis and regain the infarction so that the patients receive effective treatment.The case came from September 2009 to January 2011 patient hospitalization in the China-Japan union hospital of Jilin university, and the total case is 167 from neurology and second department neurology, the onset time was acute cerebral infarction during three days. 88patients is as routine control group. The way is Sodium Ozagrel+ Ginkgo Leaf liquid. The experimental group is 79 patients, which is added to the 0.15 human urinary kallirein except the inconventional therapy. The treatment course is ten days, two groups before treatment were carried out in the NIHSS score and BI index score, treatment after six days, ten days, fourteen days they are still the same application of NIHSS and BI index score of efficacy to research the nerve recovery. According to the time of onset to treatment, before three days and between three and seven day and after seven days.We see the observation relationship beteween medication time and effect .If the patients have checked up the relevant exam, according to the NEW-TOAST cause of cerebrovascular disease were observed. The classification of different causes is separated by AT,CE,SAD,SOD and the effect is observed.The study in experimental group NIHSS scores are lower(P<0.05),And BI expormential is increased(P<0.05).the scores are compared between two groups whether NIHSS or BI index are significant differences(P<0.05) after the fourth days.The sixth days and tenth days after treatment was not statistically significant (P>0.05). The effect is compared in different time before three days and between three and seven day and after seven days. There is a significantly difference (p<0.05). Different causes by NEW-TOAST the efficient control of AT,CE,SAD,SOD is higher than the routine group. The AT,CE,SOD is significant difference between the routine control group and experimental group (P<0.05).Though the effect of SAD is higher than control group, it was not statistically significant(P>0.05).This paper draw the following conclusions. The application of Human urinary kallirein can effectively improve neurological function .There is different effect in different onset time before three days and between three and seven day and after seven days. If you apply the drug the earlier, it may be significantly result the better. The AT, CE, SOD, SAD can make an great effect in NEW-TOAST.